SUN PHARMA ADVANCED RESEARCH COMPANY
|
SUN PHARMA ADVANCED RESEARCH COMPANY Last 5 Year Cashflow Statement History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | |
|---|---|---|---|
| Profit Before Tax | ₹-343 Cr | ₹-387 Cr | ₹-223 Cr |
| Adjustment | ₹21 Cr | ₹-11 Cr | ₹6.99 Cr |
| Changes In working Capital | ₹-47 Cr | ₹-27 Cr | ₹141 Cr |
| Cash Flow after changes in Working Capital | ₹-369 Cr | ₹-425 Cr | ₹-74 Cr |
| Cash Flow from Operating Activities | ₹-360 Cr | ₹-429 Cr | ₹-69 Cr |
| Cash Flow from Investing Activities | ₹158 Cr | ₹392 Cr | ₹-548 Cr |
| Cash Flow from Financing Activities | ₹199 Cr | ₹42 Cr | ₹617 Cr |
| Net Cash Inflow / Outflow | ₹-3.38 Cr | ₹4.74 Cr | ₹-0.64 Cr |
| Opening Cash & Cash Equivalents | ₹5.33 Cr | ₹0.58 Cr | ₹1.22 Cr |
| Cash & Cash Equivalent on Amalgamation / Take over / Merger | - | - | - |
| Cash & Cash Equivalent of Subsidiaries under liquidations | - | - | - |
| Translation adjustment on reserves / op cash balalces frgn subsidiaries | - | - | - |
| Effect of Foreign Exchange Fluctuations | ₹0.01 Cr | ₹0.00 Cr | - |
| Closing Cash & Cash Equivalent | ₹1.96 Cr | ₹5.33 Cr | ₹0.58 Cr |
Compare Cashflow Statement of peers of SUN PHARMA ADVANCED RESEARCH COMPANY
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| SUN PHARMA ADVANCED RESEARCH COMPANY | ₹7,366.2 Cr | -1.8% | 12% | 48.9% | Stock Analytics | |
| SAGILITY | ₹18,758.1 Cr | 1.1% | -3% | -2.5% | Stock Analytics | |
| SYNGENE INTERNATIONAL | ₹17,880.5 Cr | -2.8% | -5.6% | -31.7% | Stock Analytics | |
| PRIME FOCUS | ₹16,621.7 Cr | -13.4% | -11.9% | 88.9% | Stock Analytics | |
| INTERNATIONAL GEMOLOGICAL INSTITUTE | ₹15,220.7 Cr | -0.7% | -4.8% | -2.8% | Stock Analytics | |
| INDEGENE | ₹12,689.5 Cr | 2.7% | 4.3% | -6.9% | Stock Analytics | |
SUN PHARMA ADVANCED RESEARCH COMPANY Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SUN PHARMA ADVANCED RESEARCH COMPANY | -1.8% |
12% |
48.9% |
| SENSEX | -0.2% |
2.1% |
-5.6% |
You may also like the below Video Courses